A total of 9 drugs were included or proposed for priority review in May

As of May 31, a total of nine drug applications were included or are to be included in the priority review, including six innovative drugs, three generic drugs from AstraZeneca, UCB, Mylan Pharmaceuticals and Haussen Pharmaceuticals, according to a public information posted on the website of the Drug Review Center (CDE) of the State Drug Administration of ChinaThese drugs, not only aids triple therapy, but also a number of generic drugs, covering AIDS, epilepsy, heart failure, haemophilia and other indicationsfour drugs were formally included in the Priority Review1, Dagrenetinto the priority review reasons: for specific patients with heart failure adults, acting on new targets: AstraZenecaDagre net tablets is a "first-in-class" oral sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by AstraZenecaSGLT2 is a transporter protein in the kidneys that assists in glucose reabsorptionSGLT2 inhibitors reduce glucose levels in the blood by inhibiting The function of SGLT2 and allowing more glucose to be removed from the urinein China, Dagre Net was first approved in 2017 to improve blood sugar control in adults with type 2 diabetes and is the first SGLT2 inhibitor to be listed in ChinaThe listing is for a new indication that is used in adult patients with reduced blood score, reduced risk of cardiovascular death and worsening heart failure, and improved symptoms of heart failureIt's worth noting that this indication was approved by the U.SFDA in early May2, Ifiwelen/Ramifudin/Tenofowe tabletsto be included in the priority review reasons: AIDS drugCompany: Mylan Pharmaceuticalsefavirenz /lamivudine/tenofovir disoproxil fumarate) is a combination of therapies developed by Mylan Pharmaceuticals, mainly used for AIDS treatment by Mylan's subsidiary in China in the United States, the FDA has approved two treatment options for the triple combination therapy: one for SymfiLo (Iffouron 400mg/Ramifda 300mg/Fumatonovdine 300mg) tablets, and approved for the treatment of adults weighing at least 35 kg HIV-1 infection in children; another one-time tablet programme Symfi (Ifferon 600mg/Ramifdin 300mg/Fumaatindi nofovir 300mg) was approved for treatment of HIV-1 infections in adults and children weighing at least 40 kg 3, left ethyl lasitan injection of a concentrated solution included in the priority review reasons: Children's Drug Company: Usby Left Eirasitan is an anti-epileptic drug developed by Uber The drug is a pyrethyl ketone derivative, the mechanism of action is mainly combined with the special receptor synaptic vesicle protein SV2A in the brain, has central selectivity, through the polymerization of the vesion and cytospit action to regulate the release of neurotransmitters and play a role the drug was first approved for sale in the United States in 2006 and was approved in China in July 2017 and is clinically used primarily for the treatment of partial seizures (with or without secondary all-out seizures) in adults and children over 4 years of age Substitute disputation can be used when the patient is temporarily unable to apply the oral formulation of left ethyl lacitan 4, human coagulation factor VIII included in the priority review reasons: rare disease drugs Company: Yuyang Pharmaceutical s
human coagulation factor VIII Mainly used for the treatment of type A haemophilia Hemophilia is a single-gene X-linked recessive disease, characterized by the presence of active clotting enzyme production disorders Haemophilia patients may bleed longer than others after injury or surgery In addition, their muscles, joints and organs may also experience spontaneous bleeding, which can be severe and even life-threatening Hemophilia Type A is caused by the lack of coagulation factor VIII, and the replacement therapy for coagulation factor is the main means of treating haemophiliac patients five drugs to be included in the priority review 1, his fluoroprostorin eye drops included in the priority review reasons: clinically urgent, market-in-short-term drug company: Chengdu Shengdi Pharmaceuticals (Henrui Pharmaceutical subsidiary) his fluoroprostorinopathy is a new type of antiseptic-free prostatin analogue (PGA) eye drops, clinically used to reduce the increase in intra-eye pressure patients open-angle glaucoma or high-pressure eye After drug use will act on the room water drainage of the grape membrane symdural pathway, so that the tissue gap becomes loose, reduce the resistance of water drainage This promotes the discharge of fluid generated in the eye and reduces eye pressure China has not yet approved a generic drug for his fluoroprosfrontal eye drops Hengrui Pharmaceuticals subsidiary Chengdu Shengdi Pharmaceuticals' application for listing of his fluoroprosine eye drops was included in the proposed priority review, meaning that Chinese glaucoma patients are expected to soon usher in new treatment options 2, the of baritric acid Valeniklan tablets included in the priority reasons: 1 year before the expiration of the patent drug production application company: Howson Pharmaceuticals of baritisic acid is a product suitable for adult smoking cessation, the original research drug developed by Pfizer, China is currently only R-Pharm Germany GmbH production of bararic acid Valenikland in the market name Studies have shown that vannikran selectively binds to alpha4 beta2 nicotine acetylcholine receptors, producing an exagogative effect that blocks nicotine from binding to the receptor, which is the mechanism by which Valnikran acts as a quitter In a clinical trial of 15 centers in China, Singapore and Thailand, the main efficacy ended at four weeks with a significantly higher rate than the placebo group (31.6 percent) in the Valnikiran treatment group 3, tefluoroamine tablets included in the priority review reasons: rare disease drugs Company: Seishitec biomedicine tefluoroamine is an anti-inflammatory agent, can inhibit dihydrowyacid dehydrogenase, the enzyme is a mitochondriase involved in the synthesis of the head Studies have shown that the mechanism of the drug's treatment of multiple sclerosis may be related to the decrease in the number of activated lymphocytes in the central nervous system Currently, only Sanofi's Tefluoroamine has been approved for listing in China The proposed inclusion of the product in the first priority review of The World Tech co., China means that China is about to welcome the first generic drug of tefluoroamine 4, butyl phenyna tablets included in the priority review reasons: Rare Disease Drug Company: Dr Riddy Laboratories Of India, Ltd the treatment of butpenacause was originally used for the treatment of schizophrenia, in 2008 the Fda accelerated approval of its listing for huntington's disease, becoming the first and only drug in the United States to treat HD Butyl phenynain mainly reduces the supply of monoamine compounds such as serotonin, dopamine and norepinephrine by reversible inhibition of monoamine transporter 2 (VMAT 2) of the central nervous system to produce pharmacological activity it is worth mentioning that, not long ago, Teva's Anti-Titan (Teva) has just received approval from the National Drug Administration of China (NMPA) for the treatment of Huntington's disease-related dance disease and delayed motor disorders in adults The inclusion of butanine tablets in Dr Reddy's laboratory in India means that HD patients in China are expected to welcome a new treatment 5, ampicillin acid dispersion included in the priority review reasons: rare diseases and children's medicine
company: Shanghai Okoda Bio
ampicillin is a similar to gamma-aminobutyric acid (GABA), has been listed in the United States in 2018, is the FDA approved to treat infant ispasm and the use of multiple epilepsy treatments after the use of a few adult complex partial seizures of one of the effective drugs it is known that the mechanism of action of the drug is that it can specifically bind to GABA amino transferase and irreversible, resulting in an increase in the concentration of GABA in the brain, thus playing an anti-epileptic role Ampicillin acid dispersion can be used as an auxiliary treatment for patients who are not effective with other anti-epileptic drugs, especially those with partial seizures (mainly used to control complex partial seizures) The drug can also be used in infants with West syndrome (baby spasms) congratulates them on being included in the priority review or to be included in the priority review, in the hope that they will be approved for market at an early date and will lead to more treatment options for patients Reference: Retrieved May 27, 2020, from 2) Roche's ADC drug Hersele (R) has been approved to bring a new decision point for early breast cancer treatment Jan 24, 2020, from (original title: May these nine drugs were included in the priority review, to take pride, AstraZeneca, Uber.. )